Expert Interviews

Panelists discuss how delaying intervention during Stage 2 Type 1 diabetes increases the risk of diabetic ketoacidosis and complications at diagnosis, while also potentially accelerating beta cell destruction and reducing the window for preservation therapies.

Panelists discuss how Type 1 diabetes progresses through distinct stages, from initial autoimmunity with normal blood glucose (Stage 1), to dysglycemia without symptoms (Stage 2), to clinical diagnosis with symptoms (Stage 3), marking critical intervention points for treatment and management.

Panelists discuss how screening for Type 1 diabetes should focus on identifying high-risk individuals through family history, genetic markers, and autoantibody testing, while emphasizing the importance of early detection to prevent diabetic ketoacidosis at diagnosis.

Panelists discuss discusses how delayed intervention in Stage 2 Type 1 diabetes can accelerate beta cell destruction, leading to more severe clinical onset and increased risk of life-threatening complications like diabetic ketoacidosis.

Panelists discuss how Type 1 diabetes progresses through distinct stages, beginning with asymptomatic autoantibody presence, followed by abnormal blood sugar levels, and ultimately manifesting with classic symptoms like excessive thirst, frequent urination, and unexplained weight loss.

Panelists discuss how early screening for Type 1 diabetes involves testing for autoantibodies in at-risk individuals, particularly those with family history or genetic predisposition, to enable prompt intervention and reduce the risk of diabetic ketoacidosis at diagnosis.

Panelists discuss how managing Type 1 diabetes requires constant vigilance through blood sugar monitoring, insulin administration, and lifestyle adjustments to maintain healthy glucose levels throughout daily life.

Panelists discuss how obstructive sleep apnea (OSA) disrupts normal breathing during sleep through repeated upper airway collapse, leading to fragmented sleep patterns, daytime fatigue, and potential long-term health complications if left untreated.

Panelists discuss how Type 1 diabetes imposes significant physical, emotional, and financial burdens on patients through the lifelong need for insulin therapy, blood glucose monitoring, lifestyle modifications, and management of potential complications.

Robert Hopkins, Jr, MD, NFID medical director, details a range of resources on the foundation's website including in-depth vaccine recommendations, live webinars, plus much more.